In order to tailor the site to your needs, please click the button that relates best to you.
So long as you have cookies enabled you will only need to do this once. However, you can change your selection at any time using the dropdown navigation option above the CESPHN logo, top left.
This post is not the latest immunisation update and therefore may contain information or advice that is out of date. Please see our most recent update here.
From 1 October 2021 the Australian Government announced people aged 60 and over can access any brand of COVID-19 vaccine, including the Comirnaty (Pfizer) or Spikevax (Moderna) vaccines, at all vaccination sites, regardless of where they live.
This means:
people aged 18+ can access any COVID-19 vaccine (Pfizer, Moderna and Vaxzevria (AstraZeneca)); and
people aged 12+ can access the Moderna or Pfizer vaccines.
It is important that high priority and vulnerable cohorts continue to be prioritised for vaccination appointments where possible, such as home care workers, disability support workers and Aboriginal and Torres Strait Islander people, to access a COVID-19 vaccine. See Department of Health statement.
Invalid COVID-19 vaccine doses
New ATAGI clinical guidance is available on the use of an additional COVID-19 vaccine dose as a replacement dose for an invalid dose in specified scenarios of schedule deviation or vaccine administration errors, including:
Giving a replacement dose if a second COVID-19 vaccine dose was given at less than 14 days after the first dose
Giving a replacement dose for specified vaccine administration errors resulting in under-dosing
This clinical guidance does not pertain to recommendations for a third or booster dose after completion of the valid two-dose primary course according to an acceptable schedule.
This clinical guidance advice is applicable to both homologous and heterologous two dose COVID-19 vaccine schedules, including accepted non-TGA registered vaccines.
Temporary medical exemptions for COVID-19 vaccines
There are very few situations where a vaccine is contraindicated and as such, medical exemption is expected to be rarely required. ATAGI have developed guidance for providers on acute major medical conditions that warrant a temporary medical exemption relevant for COVID-19 vaccines.
Temporary medical exemptions can only be completed by eligible health professionals utilising their Medicare provider number, and can be recorded on the Australian Immunisation Register (AIR) either by:
completing the AIR Immunisation medical exemption form (IM011) (all COVID-19 brands must be selected on the form). Note: when using the IM011 form, changes may take a few weeks to be updated on the AIR.
An AIR Immunisation History Statement displays all vaccinations or medical contraindications and authorised exemptions, including COVID-19, that have been reported to the Australian Immunisation Register. There is no longer any need to use the NSW Health Medical Contraindication form.
Recognition of overseas COVID-19 vaccines
Following assessment to determine the protection offered by vaccines against infection and serious illness, TGA’s initial advice is that Coronavac (Sinovac) and Covishield (AstraZeneca/Serum Institute of India) vaccines be considered ‘recognised vaccines’ for incoming international travellers to be regarded as appropriately vaccinated.
COVID-19 vaccines which have been granted provisional approval in Australia – Pfizer (Comirnaty), AstraZeneca (Vaxzevria), Moderna (Spikevax) and COVID-19 Vaccine Janssen are also recognised for incoming travellers.
At this point in time, TGA has received insufficient data to reach a conclusion as to the protection offered by BIBP-CorV (Sinopharm), Covaxin (Bharat Biotech), Sputnik V (Gamaleya Institute), and Convidecia (CanSino). These vaccines could be recognised in the coming weeks or months as more data becomes available. See TGA statement.
Children and COVID-19 FAQs
Children aged 12 years and older are recommended to get COVID-19 vaccine and the vaccination program for this age group is underway in Australia. NCIRS has answered some of the most frequently asked questions about COVID-19 in children, vaccines available in Australia, vaccine safety and schooling. The FAQs are available on the NCIRS website.
COVID-19 vaccine safety data for people aged 12 to 19
New COVID-19 vaccine safety data from AusVaxSafety has shown adolescents aged 12–19 years are reporting similar short-term vaccine side effects to those reported by older Australians. AusVaxSafety has received more than 150,000 completed day 3 safety surveys from adolescents aged 12–19 years who received their COVID-19 vaccine and to date, the data analysis has not detected any safety signals for this age group.
Authentication file access to the Australian Immunisation Register (AIR) closed on 30 September 2021 for all providers. A Provider Digital Access (PRODA) account is required to access the AIR via the Health Professionals Online Services (HPOS) portal from this date onward. Instructions for health professionals and medical practices to set up AIR access can be found here.
COVID-19 live stream update for GPs
Join the latest COVID-19 vaccine live stream update for GPs. The panel will provide latest key updates and answer participants’ questions live about the COVID-19 vaccine rollout. Get involved by submitting questions and comments!
Register here for upcoming NCIRS webinar: Weighing up the benefits and risks of COVID-19 vaccination: a focus on safety. Consider the risks and benefits of COVID-19 vaccination and learn strategies for discussions to support your patients, friends and family in making decisions.
Date and time: Wednesday 13 October 2021, 12.30 pm – 2.00 pm AEDT
COVID-19 vaccination – Arm yourself – FAQ (new 1 Oct): This infographic is part of a suite of tools for use for businesses to encourage COVID-19 vaccination for employees.
Clinical guidance applicable in scenarios where individuals have been considered to have received an inadequate two-dose primary course, such as vaccine schedule deviation or administration errors.
Welcome to our new website! As you may have noticed, our website looks different. Central and Eastern Sydney PHN have moved to a new site and although much has remained the same, we have introduced some new functions. These include: Updated navigation When you land on our new website, you…
COVID-19 weekly update – 02 JANUARY 2023 COVID-19 cases in the region Please note: From next week the latest COVID-19 information will be included in the Sydney Health Weekly newsletter, rather than separated at the top. We will still provide COVID-19 related information as well as the dedicated COVID-19 latest…
FIVE QUESTIONS is where we ask members of the community to talk about how they stay HEALTHY. Randwick scientist and grandmother Hilda Stender shared this: What exercise did you do yesterday? I’ve had two knee replacements – one four years ago and the other six months ago. As a result,…
Immunisation weekly update – 1 February 2023 Childhood immunisation overdue reports CESPHN is inviting general practices to sign up to receive a regular report extracted on your behalf from the Australian Immunisation Register (AIR) which is specific to your practice. This report contains all children aged 0-5 living in the CESPHN region…
Australian Digital Health Agency (ADHA) digital health webinars Implementing MyHealth Record Policies in your organisation Thu 9 Feb 23, 12.30-1.00 pm – learn how to implement and maintain a My Health Record Security and Access policy in your organisation. Understand the importance of the Responsible Officer (RO) and Organisational Maintenance…
UNSW research – Palliative care and intellectual disability A research team led by Professor Julian Trollor at the Department of Developmental Disability Neuropsychiatry, UNSW Sydney, aims to design, implement, and evaluate a new palliative care service for people with intellectual disability. This is important because people with intellectual disability often…
GP support needed: Shared e-Care plan study for follow-up of colorectal and breast cancers This research evaluates shared care using a new interactive e-care plan being implemented through cancer services in Prince of Wales and St George public and private hospitals. Through the e-care plan GPs, cancer specialists and patients…